Drug
Mgcd265
Mgcd265: highest development phase Phase 1, developed by Mirati Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGCD265 NCT01930006 | Phase 1 | Advanced Malignancies |
| MGCD265 NCT00697632 | Phase 1 | Advanced Cancer |
| MGCD265 NCT00679133 | Phase 1 | Advanced Malignancies |
Latest
No recent events.
Follow Mgcd265 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.